HUS1500025I1 - KDR-re specifikus humán ellenanyagok és alkalmazásaik - Google Patents

KDR-re specifikus humán ellenanyagok és alkalmazásaik

Info

Publication number
HUS1500025I1
HUS1500025I1 HUS1500025C HUS1500025C HUS1500025I1 HU S1500025 I1 HUS1500025 I1 HU S1500025I1 HU S1500025 C HUS1500025 C HU S1500025C HU S1500025 C HUS1500025 C HU S1500025C HU S1500025 I1 HUS1500025 I1 HU S1500025I1
Authority
HU
Hungary
Prior art keywords
antibodies
kdr
human antibodies
antibodies specific
single chain
Prior art date
Application number
HUS1500025C
Other languages
English (en)
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1500025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of HUS1500025I1 publication Critical patent/HUS1500025I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HUS1500025C 2002-03-04 2015-04-28 KDR-re specifikus humán ellenanyagok és alkalmazásaik HUS1500025I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36178302P 2002-03-04 2002-03-04
PCT/US2003/006459 WO2003075840A2 (en) 2002-03-04 2003-03-04 Human antibodies specific to kdr and uses thereof

Publications (1)

Publication Number Publication Date
HUS1500025I1 true HUS1500025I1 (hu) 2017-04-28

Family

ID=27805075

Family Applications (1)

Application Number Title Priority Date Filing Date
HUS1500025C HUS1500025I1 (hu) 2002-03-04 2015-04-28 KDR-re specifikus humán ellenanyagok és alkalmazásaik

Country Status (18)

Country Link
US (2) US7498414B2 (hu)
EP (3) EP1487856B1 (hu)
JP (3) JP2005526506A (hu)
AT (2) ATE475431T1 (hu)
AU (1) AU2003213687A1 (hu)
BE (1) BE2015C027I2 (hu)
CA (1) CA2478169C (hu)
CY (3) CY1111141T1 (hu)
DE (1) DE60333554D1 (hu)
DK (2) DK1487856T3 (hu)
ES (2) ES2347543T3 (hu)
FR (1) FR15C0034I2 (hu)
HK (1) HK1118229A1 (hu)
HU (1) HUS1500025I1 (hu)
LU (1) LU92710I2 (hu)
PT (2) PT1487856E (hu)
SI (2) SI1487856T1 (hu)
WO (1) WO2003075840A2 (hu)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1487856T3 (da) * 2002-03-04 2010-10-18 Imclone Llc KDR-specifikke humane antistoffer og deres anvendelse
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
RU2402567C2 (ru) 2003-12-05 2010-10-27 Бристоль-Майерз Сквибб Компани Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
KR20130133302A (ko) * 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
US7625559B2 (en) * 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
EP2067789A1 (en) * 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
CN101613409B (zh) 2005-06-17 2014-06-04 英克隆有限责任公司 抗-PDGFRα抗体
WO2007009071A2 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
BRPI0619853A2 (pt) * 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP3156415A1 (en) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008142165A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
CA2691940C (en) * 2007-07-03 2018-03-06 Joost Alexander Kolkman Methods for providing improved immunoglobulin sequences
CA2694396A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binding agents directed to kdr and uses thereof - 035
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2011005377A2 (en) * 2009-05-27 2011-01-13 Mount Sinai School Of Medicine Of New York University Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease
WO2011041093A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
SG181495A1 (en) * 2009-12-29 2012-07-30 Univ Yale Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2862955T3 (es) 2010-10-01 2021-10-08 Modernatx Inc Acidos nucleicos manipulados y métodos de uso de los mismos
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
KR102001686B1 (ko) 2011-04-07 2019-07-18 암젠 인크 신규한 egfr 결합 단백질
MX343659B (es) 2011-06-02 2016-11-16 Dyax Corp Proteínas de unión receptoras fc.
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2854153A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2833920A2 (en) 2012-04-02 2015-02-11 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2903647B1 (en) * 2012-10-05 2020-01-01 Kadmon Corporation, LLC Human anti-vegfr-2/kdr antibodies
EP2924052B1 (en) 2012-11-21 2019-07-17 Pharmabcine Inc. Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition comprising same
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
US9618523B2 (en) * 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
BR112015021462A2 (pt) 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
TWI558399B (zh) * 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
TWI569808B (zh) 2014-08-15 2017-02-11 禮來大藥廠 肝細胞腫瘤（ｈｃｃ）之治療
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CA2995344C (en) 2014-10-07 2021-05-04 Kadmon Corporation, Llc Human anti-vegfr-2/kdr antibodies
TW201625304A (zh) 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
US10544224B2 (en) 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2017117384A1 (en) * 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
JP2019511541A (ja) * 2016-04-15 2019-04-25 イーライ リリー アンド カンパニー 結腸直腸癌の処置における使用のためのラムシルマブとメレスチニブとの組み合わせ
CN108883182A (zh) 2016-04-15 2018-11-23 伊莱利利公司 用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗
SG11201809669RA (en) 2016-05-20 2018-11-29 Biohaven Pharm Holding Co Ltd Use of glutamate modulating agents with immunotherapies to treat cancer
JP2019517507A (ja) 2016-06-03 2019-06-24 イムクローン リミテッド ライアビリティ カンパニー 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
WO2018069871A2 (en) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
JP2019534888A (ja) 2016-10-28 2019-12-05 イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ 癌の治療のための抗ｖｅｇｆｒ−２抗体と抗ｐｄ−ｌ１抗体との組み合わせ
WO2018098363A2 (en) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
CN106674349B (zh) * 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体
JP7135068B2 (ja) 2017-08-21 2022-09-12 イーライ リリー アンド カンパニー Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
CN113056285A (zh) 2018-06-29 2021-06-29 璟尚生物制药公司 抗肿瘤免疫检查点调节剂拮抗剂
AU2019385497A1 (en) 2018-11-20 2021-06-17 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
JP2022524321A (ja) 2019-03-13 2022-05-02 バスキュラー バイオジェニックス リミテッド 抗腫瘍療法の方法
JP2022540571A (ja) 2019-06-28 2022-09-16 ゲンスン バイオファーマ、インコーポレーテッド 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
AU2020368369A1 (en) 2019-10-15 2022-05-12 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN111024949A (zh) * 2019-12-31 2020-04-17 上海博威生物医药有限公司 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用
JP2023540490A (ja) 2020-09-02 2023-09-25 ファーマブシン インコーポレイテッド がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法
CN114316064A (zh) * 2020-10-10 2022-04-12 广东菲鹏制药股份有限公司 融合蛋白及其应用
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328695A (en) 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4683295A (en) 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE4103975A1 (de) 1991-02-09 1992-08-13 Thomson Brandt Gmbh Verfahren zur verkuerzung der zugriffszeit
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US20010021382A1 (en) 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
JP3670302B2 (ja) 1993-07-23 2005-07-13 ファナック株式会社 射出成形機における可塑化の管理方法
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
WO1999014234A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AT402796B (de) 1995-02-01 1997-08-25 Fritschi Apparatebau Schibindung
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
JP3658471B2 (ja) 1996-09-30 2005-06-08 株式会社日立製作所 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
AU731927B2 (en) 1996-11-21 2001-04-05 Kyowa Hakko Kirin Co., Ltd. Anti-human VEGF receptor F1t-1 monoclonal antibody
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
DE69838334T2 (de) 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
PL348634A1 (en) 1998-05-15 2002-06-03 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
CA2359461A1 (en) 1999-01-15 2000-07-20 Medstar Research Institute Inhibiting development of microvessels within vascular walls
CA2361553A1 (en) 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6524583B1 (en) 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
KR20020087453A (ko) 2000-03-31 2002-11-22 임클론 시스템즈 인코포레이티드 혈관 내피 성장 인자 수용체 길항제를 사용한, 포유동물의비충실성 종양의 치료 방법
JP2004511430A (ja) 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
EP1515707A4 (en) 2001-06-20 2005-10-19 Imclone Systems Inc METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER INFLAMMATORY DISEASES
US20040242851A1 (en) 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
US6519852B1 (en) 2001-07-26 2003-02-18 Yuecom Manufacturing Co., Ltd. Method of manufacturing an aluminum alloy wheel rim
DK1487856T3 (da) * 2002-03-04 2010-10-18 Imclone Llc KDR-specifikke humane antistoffer og deres anvendelse
US6844779B2 (en) 2003-06-19 2005-01-18 The United States Of America As Represented By The Secretary Of The Air Force Optically isolated bias control circuit

Also Published As

Publication number Publication date
EP1487856A4 (en) 2006-08-23
EP1487856A2 (en) 2004-12-22
FR15C0034I2 (fr) 2016-08-26
SI1916001T1 (sl) 2011-10-28
US20090142358A1 (en) 2009-06-04
PT1487856E (pt) 2010-09-29
JP2012105667A (ja) 2012-06-07
EP1916001B1 (en) 2011-05-25
EP1487856B1 (en) 2010-07-28
US20050234225A1 (en) 2005-10-20
LU92710I2 (fr) 2015-11-02
DK1487856T3 (da) 2010-10-18
WO2003075840A2 (en) 2003-09-18
JP5476404B2 (ja) 2014-04-23
CY1111141T1 (el) 2015-06-11
CA2478169A1 (en) 2003-09-18
CY1111629T1 (el) 2015-10-07
JP2009148298A (ja) 2009-07-09
DK1916001T3 (da) 2011-07-18
EP1916001A3 (en) 2008-08-13
CY2015018I2 (el) 2016-04-13
AU2003213687A1 (en) 2003-09-22
FR15C0034I1 (fr) 2015-06-26
JP2005526506A (ja) 2005-09-08
ES2347543T3 (es) 2010-11-02
US8057791B2 (en) 2011-11-15
BE2015C027I2 (hu) 2022-05-19
WO2003075840A3 (en) 2004-04-29
SI1487856T1 (sl) 2010-12-31
EP2298346A2 (en) 2011-03-23
HK1118229A1 (en) 2009-02-06
ATE475431T1 (de) 2010-08-15
US7498414B2 (en) 2009-03-03
EP2298346A3 (en) 2011-11-16
ES2362931T3 (es) 2011-07-15
DE60333554D1 (de) 2010-09-09
AU2003213687A8 (en) 2003-09-22
ATE510561T1 (de) 2011-06-15
JP4970483B2 (ja) 2012-07-04
CY2015018I1 (el) 2016-04-13
CA2478169C (en) 2013-04-16
PT1916001E (pt) 2011-07-18
EP1916001A2 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
HUS1500025I1 (hu) KDR-re specifikus humán ellenanyagok és alkalmazásaik
CY1113037T1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
NO2017032I1 (no) bezlotoksumab
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
CY1114784T1 (el) Αντισωματα εναντι σκληροστινης
NO20171697A1 (no) IL-17 Antagonistiske antistoffer
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
NZ591056A (en) Human cytomegalovirus neutralizing antibodies and use thereof
MY156315A (en) Anti-vegf antibodies
DE602006013029D1 (de) Anti-egfr-antikörper
DK1706424T3 (da) FC-region varianter
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
ATE412432T1 (de) Internalisierende erbb2 antikörper
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
MY187975A (en) Antigen-binding proteins that activate the leptin receptor
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
WO2008085878A3 (en) High affinity antibodies that neutralize staphylcoccus enterotoxin b
WO2004113500A3 (en) B7s1: an immune modulator
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
CY1113852T1 (el) Βελτιστοποιημενα αντισωματα που στοχευουν to cd19